A new report published by Fact.MR estimates the global kidney cancer diagnostics market to exhibit an impressive expansion at during the forecast period 2017 to 2022. In terms of revenues, the global market for kidney cancer diagnostics will reach nearly US$ 700 Mn by 2022-end.
Kidney cancer has been witnessed to occur majorly in older population. Diagnosis of kidney cancer becomes an intricate task, considering the condition of geriatric patients. While staple diagnostic technologies such as MRI and CT scan continue to play a pivotal role in the global market, patients are also expecting the emergence of all-inclusive diagnosis tests. Medical organizations are also funneling high investments in R&D of kidney cancer diagnostics, particularly to improve the precision of early stage diagnosis tests. Through advancements in medical technology, the global market for kidney cancer diagnostics is also expected to witness emergence of new tests that can simultaneously decelerate the pace of tumor maturation between multiple stages of kidney cancer.
Request Sample Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=56
The report on the global market for kidney cancer discusses such key factors that govern the economics of kidney cancer diagnostics across the globe. Some of the key influences for the growth of global kidney cancer diagnostics market include:
Rising presence of carcinogenic elements in common consumables
Surging exposure to toxic substances in factories & industrial settings
Lack of awareness related to causes, symptoms, and preventive measures for kidney cancer
High healthcare costs, deterring kidney cancer patients from seeking optimum diagnosis
With growing incidence of kidney cancer, the future generations will witness a more accessible, affordable, and diagnosis-associated treatment for kidney cancer. As kidney cancer research organizations & societies struggle to develop effective medications in tight-budgeted capitals, governments are deploying initiatives that boost the awareness of kidney cancer.
Browse Full Report with TOC-
https://www.factmr.com/report/56/kidney-cancer-diagnostics-market
Hospital-associated Labs will Remain Preferred for Kidney Cancer Diagnostics
On the basis of end-users, hospital-associated labs are estimated to remain preferred for kidney cancer diagnostics, accounting for the largest revenues by 2022-end. Independent diagnostic laboratories will continue to be the second most lucrative end-users in the global kidney cancer diagnostics market. In addition, cancer research institutes are expected to register the highest CAGR in the market through 2022.
Immunochemistry tests will continue to be sought-after for kidney cancer diagnostics, with revenues expected to reach US$ 351.8 Mn by 2022-end. This test type segment is projected to register the highest CAGR in the market through 2022, followed by complete blood count test.
The report has also profiled leading players in the global market for kidney cancer diagnostics, which include NeoGenomics Laboratories, Myriad Genetics Inc, NanoString Technologies Inc., Rosetta Genomics, Sysmex Corporation, Illumina, Inc., Roche Holding AG, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., and Abbott Laboratories.
For More Information Send Enquiry:
https://www.factmr.com/connectus/sample?flag=AE&rep_id=56
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at - https://www.industrynewsanalysis.com/
Read Full PR:
https://www.factmr.com/media-release/42/kidney-cancer-diagnostics-market
